Active, not recruitingPhase 2NCT03224767
Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma
Studying Craniopharyngioma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Alliance for Clinical Trials in Oncology
- Principal Investigator
- Priscilla K. Brastianos, MDMassachusetts General Hospital
- Intervention
- Vemurafenib(drug)
- Enrollment
- 24 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2018 – 2028
Study locations (30)
- University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
- Sutter Cancer Centers Radiation Oncology Services-Auburn, Auburn, California, United States
- Alta Bates Summit Medical Center-Herrick Campus, Berkeley, California, United States
- Mills-Peninsula Medical Center, Burlingame, California, United States
- Sutter Cancer Centers Radiation Oncology Services-Cameron Park, Cameron Park, California, United States
- Eden Hospital Medical Center, Castro Valley, California, United States
- Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States
- Memorial Medical Center, Modesto, California, United States
- Palo Alto Medical Foundation-Camino Division, Mountain View, California, United States
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
- Palo Alto Medical Foundation Health Care, Palo Alto, California, United States
- Sutter Cancer Centers Radiation Oncology Services-Roseville, Roseville, California, United States
- Sutter Roseville Medical Center, Roseville, California, United States
- Sutter Medical Center Sacramento, Sacramento, California, United States
- California Pacific Medical Center-Pacific Campus, San Francisco, California, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03224767 on ClinicalTrials.govOther trials for Craniopharyngioma
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07177482ImmunoPET Targeting Trophoblast Cell-surface Antigen 2 (Trop-2) in Craniopharyngioma PatientsDeling Li
- RECRUITINGNCT06801756Craniopharyngioma and PregnanciesAssistance Publique - Hôpitaux de Paris
- RECRUITINGPHASE2NCT05525273Treatment of BRAF ( B-Rapidly Accelerated Fibrosarcoma) Mutated Papillary CraniopharyngiomaEva Marie Erfurth, MD, PhD
- RECRUITINGPHASE2NCT05465174Tovorafenib for Treatment of Craniopharyngioma in Children and Young AdultsSabine Mueller, MD, PhD
- ENROLLING BY INVITATIONNCT03610906Prospective Pilot Study Identifying Clinically Relevant Biological Targets for Medical TherapyUniversity of Colorado, Denver
- ACTIVE NOT RECRUITINGPHASE2NCT02792582A Phase II Trial of Intensity-Modulated Proton Therapy for Incompletely Resected Craniopharyngioma and Observation for Craniopharyngioma After Radical ResectionSt. Jude Children's Research Hospital
- ACTIVE NOT RECRUITINGPHASE2NCT01419067A Phase II Trial of Limited Surgery and Proton Therapy for Craniopharyngioma or Observation After Radical ResectionSt. Jude Children's Research Hospital